Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
- 16 January 2014
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 44 (2), 513-522
- https://doi.org/10.1183/09031936.00146413
Abstract
Chronic respiratory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disease (COPD) and lung cancer, are the second leading cause of death among Europeans. Despite this, there have been only a few therapeutic advances in these conditions over the past 20 years. In this review we provide evidence that targeting the epidermal growth factor receptor (EGFR) signalling pathway may represent a novel therapeutic panacea for treating chronic lung disease. Using evidence from human patient samples, transgenic animal models, and cell and molecular biology studies we highlight the roles of this signalling pathway in lung development, homeostasis, repair, and disease ontogeny. We identify mechanisms underlying lung EGFR pathway regulation and suggest how targeting these mechanisms using new and existing therapies has the potential to improve future lung cancer, COPD and pulmonary fibrosis patient outcomes.This publication has 93 references indexed in Scilit:
- Mig6 Is a Sensor of EGF Receptor Inactivation that Directly Activates c-Abl to Induce Apoptosis during Epithelial HomeostasisDevelopmental Cell, 2012
- Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signallingNature, 2012
- Genome-wide association and large-scale follow up identifies 16 new loci influencing lung functionNature Genetics, 2011
- Feedback regulation of EGFR signalling: decision making by early and delayed loopsNature Reviews Molecular Cell Biology, 2011
- A small-cell lung cancer genome with complex signatures of tobacco exposureNature, 2009
- Lrig1 Expression Defines a Distinct Multipotent Stem Cell Population in Mammalian EpidermisCell Stem Cell, 2009
- Functional selectivity of EGF family peptide growth factors: Implications for cancerPharmacology & Therapeutics, 2009
- Ligand-induced ErbB receptor dimerizationExperimental Cell Research, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interfaceNature, 2007